Rapid, single-step precision engineering and pre-clinical evaluation of chimeric antigen receptor Regulatory T cells for Type 1 diabetes

患者源性调节性T（Treg）细胞的离体工程有望成为安全有效的方法 治疗1型糖尿病（T1D）。尽管有前景的临床前研究，相当多的生物和技术， 在实现这一治疗策略之前，必须克服障碍。首先，Treg细胞必须经过工程改造， 以最佳地增强它们的特异性、稳定性和功能性。第二，可扩展性问题-或生成 必须克服患者来源的离体工程化细胞的足够产量以构成治疗剂量的问题。 没错Inc.正在通过其Hydropore ™平台解决所有这些挑战。Hydropore ™采用天然的 发生流体动力学现象-涡旋脱落-以使Treg细胞工程化， 在更短的时间内解决稳定性、功能性和可扩展性问题， 方法和电穿孔。HydroporeTM最终导致更有效的工程化T细胞，如TcB。 在这份报告中，Indee。Inc.将在下一个工程中展示Hydropore ™的技术性能。 产生用于T1D的嵌合抗原受体调节性T细胞（CAR-T细胞）。研究还将侧重于 证明了使用HydroporeTM工程化的CAR-T细胞的上级体外和体内生物活性 相对于使用传统方法设计的那些。在成功实现这些目标之前， 将使用从T1D患者分离的Treg细胞工程化CAR-T细胞，并证明其临床和生物学特性。 商业规模的加工和富集足够的CAR-TcR细胞用于人体试验。

Ex vivo engineering of patient-derived regulatory T (Treg) cells holds promise as a safe and effective approach for treating type 1 diabetes (T1D). Despite promising preclinical studies, considerable biological and technical hurdles must be addressed before this therapeutic strategy can be realized. First, Treg cells must be engineered to optimally enhance their specificity, stability, and functionality. Second, scalability issues – or generating sufficient yield of patient-derived, ex vivo engineered cells to constitute a therapeutic dose – must be overcome. Indee. Inc. is addressing all of these challenges with their Hydropore™ platform. Hydropore™ uses a naturally occurring fluid dynamics phenomenon – vortex shedding – to enable Treg cell engineering that enhances the stability, functionality, and scalability issues in less time than the current gold standards that use virus-based methods and electroporation. HydroporeTM ultimately results in more effective engineered T cells such as Tregs. In this proposal, Indee. Inc. will demonstrate the technical performance of Hydropore™ in engineering the next generation of chimeric antigen receptor regulatory T cells (CAR-Tregs) for T1D. Studies will also focus on demonstrating the superior in vitro and in vivo biological activity of CAR-Tregs engineered using HydroporeTM relative to those engineered using traditional methods. Pending the successful completion of these objectives, CAR-Tregs will be engineered using Treg cells isolated from T1D patients and demonstrate clinical- and commercial-scale processing and enrichment of sufficient CAR-Tregs cells for human trials.